JPRN-jRCT2080222030未知3 期
A phase 3, open-label, extension study of S-6810 in patients with mycosis fungoides or Sezary syndrome
适应症
试验速览
- 阶段
- 3 期
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Main inclusion criteria
- •1. Patients who completed the phase 2 open-label study.
排除标准
- •Main exclusion criteria
- •1. Patients whose therapy evaluation in the phase 2 open-label study was progressive disease, or patients who got worse in obvious at end of administration.
- •2. Patients who withdrew from the phase 2 open-label study.
研究者
相似试验
未知
2 期
A phase 2, open-label study of S-6810 in patients with mycosis fungoides or Sezary syndromeMycosis fungoides or Sezary syndromeJPRN-jRCT2080221783SHIONOGI & CO., LTD.15
进行中（未招募）
2 期
A phase II, open-Label, extension study of NS-089/NCNP-02 in patients with Duchenne muscular dystrophyDuchenne muscular dystrophyJPRN-jRCT2031210162Taira Masafumi6
未知
3 期
Add-on, open-label, phase III study of CS-866AZEssential hypertensionJPRN-jRCT2080220290DAIICHISANKYO Co.,Ltd.
进行中（未招募）
不适用
An Open-Label, Phase II Extension Study of MDX-060 in Patients with Relapsed or Refractory Hodgkin’s Disease Previously Treated in Protocol MDX060-03Relapsed or Refractory Hodgkin’s DiseaseMedDRA version: 5.0Level: LLTClassification code 10020266EUCTR2004-005040-27-GBMedarex, Inc.
进行中（未招募）
不适用
An Open-Label, Phase II Extension Study of MDX-060 in Patients with Relapsed or Refractory Hodgkin’s Disease Treated in Protocol MDX060-03 - not availableRelapsed or Refractory Hodgkin’s DiseaseMedDRA version: 5.0Level: LLTClassification code 10020266EUCTR2004-005040-27-DEBristol-Myers Squibb Company84